| Literature DB >> 22924607 |
Ifeyinwa Osunkwo1, Thomas R Ziegler, Jessica Alvarez, Courtney McCracken, Korin Cherry, Chinyere E Osunkwo, Solomon F Ofori-Acquah, Samit Ghosh, Adeolu Ogunbobode, Jim Rhodes, James R Eckman, Carlton Dampier, Vin Tangpricha.
Abstract
We report results of a pilot study of high-dose vitamin D in sickle cell disease (SCD). Subjects were given a 6-week course of oral high-dose cholecalciferol (4000-100 000 IU per week) or placebo and monitored prospectively for a period of six months. Vitamin D insufficiency and deficiency was present at baseline in 82·5% and 52·5% of subjects, respectively. Subjects who received high-dose vitamin D achieved higher serum 25-hydroxyvitamin D, experienced fewer pain days per week, and had higher physical activity quality-of-life scores. These findings suggest a potential benefit of vitamin D in reducing the number of pain days in SCD. Larger prospective studies with longer duration are needed to confirm these effects.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22924607 PMCID: PMC3460143 DOI: 10.1111/bjh.12019
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 6.998